The international biotech and pharma community will converge upon the city of Suzhou, China, a rapidly growing base for life science industries, at ChinaBio® Partnering Forum 2012 at the Kempinski Hotel Suzhou, May 23–24. Co-organizers EBD Group, the leading partnering firm for the life science industry, and ChinaBio® LLC, a leading consulting firm in Shanghai, report that over 700 industry leaders are set to attend including Aosaikang Pharmaceutical, AstraZeneca, Bayer HealthCare, BeiGene, Boehringer Ingelheim, Eli Lilly, Fosun Pharma, Furen Pharma, Hanmi Pharmaceutical, Hengrui Pharmaceuticals, Hua Medicine, Janssen/J&J, Life Technologies, Lonza, Merck, Novartis, Shire, Simcere and Takeda.
“Life science partnerships in China are growing,” said Carola Schropp, President of EBD Group. “Western companies are eager to invest in Chinese biotech innovation, helping mitigate costs and risks for both parties. ChinaBio Partnering Forum is where exciting new ‘homegrown’ innovation can be found and deals that drive the future of medicine can be made.”
“China is investing over $200 billion in its life science industry which is stimulating the development of new, innovative drugs here,” said Greg Scott, CEO of ChinaBio® LLC. “And with China’s rise to the #3 market last year, global pharma are now bringing western technologies to China, seeking partners to help them access this large and rapidly growing market. This has now become a significant part of our business – helping western companies find best-fit partners in China.”
The Partnering Forum’s program is designed to highlight the wealth of life sciences opportunities in China, and comprises high-level speakers to address pressing questions about China’s business landscape, including questions about intellectual property protection, cultural differences, and other unique challenges of doing business in China.
Program highlights include the keynote panel “Partnering Landscape in China: Going Global,” with panelists Dr. Lianshan Zhang of Jiangsu Hengrui Medicine Co. and Dr. Mingqiang Zhang of Merck Sharp &Dohme. The plenary session “Novel Drug Development in China” features CEOs of four companies leading drug development in China: Dr. Li Chen of Hua Medicine; Dr. Carl Firth of ASLAN Pharmaceuticals; John Oyler of BeiGene; and Dr. Jinzi Wu of Ascletis.
“Capturing innovation is an important theme at ChinaBio this year,” said John Oyler. “Our panel on novel drug development will provide a forum for companies interested in doing business in China but who are unsure of the business development landscape. The session will answer some of these questions and discuss successful business models to capitalize on development and commercialization opportunities in China.”
Timely other topics featured at ChinaBio® Partnering Forum include “Venture Capital and Private Equity Landscape in China” and “Deconstructing the China Deal,” and “The Good, the Bad and the Ugly: Have You Got What It Takes To Participate in the China Life Sciences Market?”
Mark Lotter, CEO of SciClone Pharmaceuticals China Operations, along with Siddhartha C. Kadia, President of Life Technologies China, will participate in a fireside chat on Thursday moderated by Eric Pierce from BioCentury. The session entitled, “The Road to China: A Fireside Chat” is focused on the hurdles and rewards of doing business in China.
“The fireside chat format will open up discussion about the challenges and successes in establishing a business relationship with China. It will be revealing to hear some personal experiences and highlights from executives with a footing in the Chinese sector,” said Lotter.
“We can no longer underestimate China as a global force in any market,” said Kadia. “And we can’t assume that it is only Western markets that are creating the demand for top quality products. Chinese scientists, patients and doctors are also part of this demand, and this is a meaningful trend that will lead to impactful partnerships.”
ChinaBio® Partnering Forum is the premier life science partnering event in China. Held in Suzhou, China, the event will attract biotech and pharma leaders from around the world along with hundreds of China-based developers of novel technologies for two days of productive partnering.
ChinaBio® Partnering Forum 2011 had more than 650 delegates from 370 companies and 24 countries, making it the largest partnering conference in China. The Innovation Showcase is returning in 2012, featuring top researchers from leading institutes and universities throughout China, including several recipients of China’s prestigious 1000 Talents Program award.
The conference also features partneringONE®, enabling delegates to efficiently identify, meet and network with companies from across the life science value chain.
Online registration for the conference will close on May 17, 2012, 5:00 PM PDT, after which all registrations will be handled on site. Information on the conference and registration details can be found online at www.ebdgroup.com/cbpf/registration.
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
Since its founding in January, 2007, ChinaBio® LLC has rapidly created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped global life science companies identify over 400 licensing and acquisition opportunities in China and China companies raise over USD 450 million.
More information is available at www.chinabiollc.com
EBD Group, Inc.
2032 Corte del Nogal, Suite 120
Carlsbad, CA 92011 USA
+1 760 930 0500
780 Cailun Road, #822
Shanghai 201203 China
From China: +86 21 5137 0751 ext 20
From USA: +1 858 926 4566 ext 12